US 10376510
2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
granted A61KA61K31/505A61K31/506
Quick answer
US patent 10376510 (2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer) held by Agios Pharmaceuticals, Inc. expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Agios Pharmaceuticals, Inc.
- Grant date
- Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/505, A61K31/506, A61K45/06, A61P